Tadalafil

Tadalafil, in the forms sold as Adcirca and Alyq for pulmonary arterial hypertension (PAH), is a phosphodiesterase 5 (PDE5) inhibitor. The US labels of both products list treating PAH (WHO Group 1) to improve exercise ability. This page covers the pulmonary arterial hypertension use. Tadalafil also has a separate US label for erectile dysfunction and for benign prostatic hyperplasia, which this page does not describe. The label says tadalafil inhibits PDE5, the enzyme that breaks down cyclic guanosine monophosphate.

Also called ADCIRCA · ALYQ

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 358263; UNII 742SXX0ICT. MeSH D000068581 is Tadalafil, with Cialis among its entry terms (a lookup on 2026-11-18, hash only), and carries no scope note, so it is recorded as an exact match for identity only. RxClass lists the established pharmacologic class Phosphodiesterase 5 Inhibitor, so the record is filed under the PDE5 inhibitor page for pulmonary hypertension. The labels read are Adcirca (United Therapeutics Corporation, NDA022332, effective 2025-12-15 in openFDA) and Alyq (Teva Pharmaceuticals, Inc., ANDA216932, effective 2023-04-01). The Cialis label (NDA021368, effective 2026-06-03) was read only for its indication sentences. Drugs@FDA also holds fixed combinations with another ingredient, which a single-ingredient match would not include; they were not read. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP).

Claims and evidence

Context Patients with pulmonary arterial hypertension, as described in the US labels of Adcirca and Alyq

Recipient
Recipient not specified
Population
Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the labels state. The passage read gives no age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the labels state. The passage read gives no age range.
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Adcirca (tadalafil, United Therapeutics Corporation, application NDA022332; the version dated 2025-12-15 in openFDA) calls the medicine a phosphodiesterase 5 (PDE5) inhibitor. It lists treating pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. The US label of Alyq (tadalafil tablets, Teva Pharmaceuticals, Inc., application ANDA216932; the version dated 2023-04-01 in openFDA) lists the same use.

    Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US labels of Adcirca and Alyq

    Certainty method
    Not assessed
    Limitations
    This claim is tied to the two pulmonary arterial hypertension labels named. The substance also has separate labels for other uses, which are not recorded here. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (6)
    1. Background openFDA drug label record for Adcirca (tadalafil tablets), United Therapeutics Corporation label: indication wording and mechanism (class page)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id ff61b237-be8e-461b-8114-78c52a8ad0ae (manufacturer United Therapeutics Corporation, application NDA022332), returned on 2026-11-18. The label text is dated 2025-12-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read, NDA022332.
      Retrieved
      Source effective date
      2025-12-15
      Source state
      Current
      Version fingerprint
      842c342248c8be4ffaa382bf9f35083a88a1f4e85dc21f70e1ccd15ee9129532
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Adcirca (tadalafil tablets), United Therapeutics Corporation label: indication wording and mechanism (class page)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id ff61b237-be8e-461b-8114-78c52a8ad0ae (manufacturer United Therapeutics Corporation, application NDA022332), returned on 2026-11-18. The label text is dated 2025-12-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20251215.
      Retrieved
      Source effective date
      2025-12-15
      Source state
      Current
      Version fingerprint
      842c342248c8be4ffaa382bf9f35083a88a1f4e85dc21f70e1ccd15ee9129532
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for Adcirca (tadalafil tablets), United Therapeutics Corporation label: indication wording and mechanism (class page)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id ff61b237-be8e-461b-8114-78c52a8ad0ae (manufacturer United Therapeutics Corporation, application NDA022332), returned on 2026-11-18. The label text is dated 2025-12-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (Q-K30-TAD-LB-04).
      Retrieved
      Source effective date
      2025-12-15
      Source state
      Current
      Version fingerprint
      842c342248c8be4ffaa382bf9f35083a88a1f4e85dc21f70e1ccd15ee9129532
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Background openFDA drug label record for Alyq (tadalafil tablets, USP), Teva Pharmaceuticals, Inc. label: indications

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 2faa7a55-3054-456b-8465-6ea6dc1c0aa9 (manufacturer Teva Pharmaceuticals, Inc., application ANDA216932), returned on 2026-11-18. The label text is dated 2023-04-01 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the Alyq label read, ANDA216932.
      Retrieved
      Source effective date
      2023-04-01
      Source state
      Current
      Version fingerprint
      47997986bf19175c15349dd70340939659f81639a533059b7758bd2fdb5c7cff
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Background openFDA drug label record for Alyq (tadalafil tablets, USP), Teva Pharmaceuticals, Inc. label: indications

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 2faa7a55-3054-456b-8465-6ea6dc1c0aa9 (manufacturer Teva Pharmaceuticals, Inc., application ANDA216932), returned on 2026-11-18. The label text is dated 2023-04-01 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the Alyq label text read, 20230401.
      Retrieved
      Source effective date
      2023-04-01
      Source state
      Current
      Version fingerprint
      47997986bf19175c15349dd70340939659f81639a533059b7758bd2fdb5c7cff
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    6. Supports openFDA drug label record for Alyq (tadalafil tablets, USP), Teva Pharmaceuticals, Inc. label: indications

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 2faa7a55-3054-456b-8465-6ea6dc1c0aa9 (manufacturer Teva Pharmaceuticals, Inc., application ANDA216932), returned on 2026-11-18. The label text is dated 2023-04-01 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (Q-K30-TAD-AL-03).
      Retrieved
      Source effective date
      2023-04-01
      Source state
      Current
      Version fingerprint
      47997986bf19175c15349dd70340939659f81639a533059b7758bd2fdb5c7cff
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:tadalafil
Content hash
20c74684d9a65f914c36826b968c3e21da91299b721d5eeb9c8023d1c33fa923